Loading
Life sciences · Journal article
Cellular Oncology · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer-associated extrachromosomal DNA (ecDNA) increases intratumoral heterogeneity through non-Mendelian inheritance, high-copy-number oncogene amplification, and structural plasticity, thereby facilitating clonal selection under therapeutic pressure. Following chemotherapy or molecularly targeted therapy, ecDNA may undergo copy-number gain or loss, transient loss and re-emergence after treatment withdrawal, structural remodeling, and switching of amplification topology between extrachromosomal and intrachromosomal forms. These changes may reflect selection of pre-existing low-frequency ecDNA subclones, copy-number adjustment or structural remodeling of existing ecDNA, or treatment-associated de novo ecDNA formation. This review summarizes the roles of ecDNA in treatment adaptation and acquired resistance, with emphasis on origin attribution using longitudinal and multiregional sampling, breakpoint lineage tracing, single-cell tracking, and structure-specific functional validation. It also discusses potential vulnerabilities involving ecDNA biogenesis, replication stress, aberrant transcription, and ecDNA maintenance. Taken together, the evidence reviewed here is more consistent with treatment-mediated selection of pre-existing ecDNA subclones and copy-number adjustment or structural remodeling of existing ecDNA than with treatment-associated de novo ecDNA formation, for which direct in vivo evidence remains limited. Clinical translation will require standardized detection methods, reliable biomarkers for patient stratification, and clearly defined therapeutic windows.